Related Experiment Video
Updated: Feb 14, 2026

FRET Microscopy for Real-time Monitoring of Signaling Events in Live Cells Using Unimolecular Biosensors
Published on: August 20, 2012
Shedding new light on RhoA signalling as a drug target in vivo using a novel RhoA-FRET biosensor mouse
Max Nobis1, David Herrmann1, Sean C Warren1
1The Garvan Institute of Medical Research, St Vincent's Clinical School, Faculty of Medicine, University of New South Wales , Sydney, 2010 NSW, Australia.
Abstract:
The small GTPase RhoA is a master regulator of signalling in cell-extracellular matrix interactions. RhoA signalling is critical to many cellular processes including migration, mechanotransduction, and is often disrupted in carcinogenesis. Investigating RhoA activity in a native tissue environment is challenging using conventional biochemical methods; we therefore developed a RhoA-FRET biosensor mouse, employing the adaptable nature of intravital imaging to a variety of settings. Mechanotransduction was explored in the context of osteocyte processes embedded in the calvaria responding in a directional manner to compression stress. Further, the migration of neutrophils was examined during in vivo "chemotaxis" in wound response. RhoA activity was tightly regulated during tissue remodelling in mammary gestation, as well as during mammary and pancreatic carcinogenesis. Finally, pharmacological inhibition of RhoA was temporally resolved by the use of optical imaging windows in fully developed pancreatic and mammary tumours in vivo. The RhoA-FRET mouse therefore constitutes a powerful tool to facilitate development of new inhibitors targeting the RhoA signalling axis.
Insights
Researchers developed a novel RhoA-FRET biosensor mouse to study RhoA signaling in vivo. This tool enables real-time observation of RhoA activity in various physiological and pathological conditions, aiding in the development of new cancer therapies.
Area of Science:
- Cellular signaling and mechanotransduction
- Cancer biology and therapeutics
- In vivo imaging and biosensing
Background:
- The small GTPase RhoA is a key regulator of cell-extracellular matrix interactions, crucial for processes like migration and mechanotransduction.
- Dysregulated RhoA signaling is implicated in carcinogenesis, but studying its activity in native tissues is challenging with conventional methods.
- Intravital imaging offers a promising approach for real-time analysis of cellular signaling within living organisms.
Purpose of the Study:
- To develop and validate a RhoA-FRET biosensor mouse for investigating RhoA activity in vivo.
- To utilize this tool to explore RhoA signaling dynamics in diverse physiological and pathological contexts.
- To enable temporal resolution of pharmacological interventions targeting RhoA signaling in vivo.
Main Methods:
- Development of a genetically engineered mouse model expressing a RhoA-Förster Resonance Energy Transfer (FRET) biosensor.
- Application of intravital imaging techniques to visualize RhoA activity in various tissues and conditions.
- Analysis of RhoA signaling during mechanotransduction, neutrophil migration, tissue remodeling, and carcinogenesis.
Main Results:
- Demonstrated RhoA-FRET mouse's capability to visualize RhoA activity in osteocyte mechanotransduction, neutrophil chemotaxis, and mammary gland remodeling.
- Observed tightly regulated RhoA activity during mammary and pancreatic carcinogenesis.
- Successfully resolved the temporal effects of RhoA inhibition in established mammary and pancreatic tumors in vivo.
Conclusions:
- The RhoA-FRET biosensor mouse is a powerful tool for studying RhoA signaling in native tissue environments.
- This model facilitates real-time investigation of RhoA's role in diverse biological processes and diseases.
- The developed tool can accelerate the discovery and development of novel therapeutic inhibitors targeting the RhoA signaling axis.
Related Concept Videos
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenomics: Identification of New Drug Targets
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
What is Cell Signaling?
Endocrine Signaling

